Athena Countouriotis

2020

In 2020, Athena Countouriotis earned a total compensation of $15.3M as President and Chief Executive Officer at Turning Point Therapeutics, a 388% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$539,400
Option Awards$14,131,423
Salary$580,000
Other$11,400
Total$15,262,223

Countouriotis received $14.1M in option awards, accounting for 93% of the total pay in 2020.

Countouriotis also received $539.4K in non-equity incentive plan, $580K in salary and $11.4K in other compensation.

Rankings

In 2020, Athena Countouriotis' compensation ranked 389th out of 13,090 executives tracked by ExecPay. In other words, Countouriotis earned more than 97.0% of executives.

ClassificationRankingPercentile
All
389
out of 13,090
97th
Division
Manufacturing
136
out of 5,621
98th
Major group
Chemicals And Allied Products
46
out of 2,254
98th
Industry group
Drugs
40
out of 1,954
98th
Industry
Pharmaceutical Preparations
28
out of 1,459
98th
Source: SEC filing on April 29, 2022.

Countouriotis' colleagues

We found four more compensation records of executives who worked with Athena Countouriotis at Turning Point Therapeutics in 2020.

2020

Siegfried PHD

Turning Point Therapeutics

Chief Scientific Officer

2020

Annette North

Turning Point Therapeutics

General Counsel

2020

Yi Larson

Turning Point Therapeutics

Chief Financial Officer

2020

Mohammad Hirmand

Turning Point Therapeutics

Chief Medical Officer

News

In-depth

You may also like